Microvast (MVST) Q3 2026 Earnings Call Transcript

Microvast (MVST) reported a 62.8% revenue decline in Q3 2026, with sales dropping to $77.5M due to reduced demand in Europe, APAC, and the US. Gross margin fell to 5.2% from 37.6% in 2025, impacted by inventory write-downs and pricing pressures. Operating expenses rose 118.8%, including litigation provisions and R&D costs. The company reported a GAAP net loss of $76.8M, with adjusted EBITDA at -$60.8M, compared to a profit last year.

Original reporting
Published Nov 10, 2026, 3:16 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 10, 2026, 3:27 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Microvast (MVST) Q3 2026 Earnings Call Transcript — source image
Decision brief

The 30-second read

$MVSTBearishMed
01

Why it matters

The earnings miss is likely to trigger a sell‑off, especially given the lack of positive guidance.

02

Market read

First disclosure of Microvast's Q3 2026 financials, providing fresh data for traders.

03

What to watch

Potential cost‑mitigation measures and upcoming tax changes could improve margins later in 2027.

Relevance 7/10Novelty 8/10Timing: after-hours earnings release

Background

Microvast (MVST) held its Q3 2026 earnings call, reporting steep revenue declines, margin compression, and a sizable net loss.

Company-level read

Ticker impact

$MVSTBearishHigh confidence
Context

Microvast disclosed Q3 2026 results with a 62.8% revenue drop and a $76.8M GAAP net loss, indicating severe earnings weakness.

Expected impact

downward pressure as investors price in weaker sales and margin compression.

Evidence & confidence

The disclosed revenue decline, margin squeeze, and sizable net loss are material new facts that can move the stock immediately.

Market effects

Highlights weakness in the lithium‑battery manufacturing sector and may pressure peers.

Signals challenges for battery makers in Europe and APAC amid regulatory and demand headwinds.

Adds to broader concerns about EV supply chain profitability.

Counterpoint

If the company can secure new contracts or government subsidies, the stock may rebound on a turnaround narrative.

Key entities

  • Yang Wu

    Founder, Chairman and CEO of Microvast.

  • Rodney Worthen

    Chief Financial Officer of Microvast.

Related articles

$MVSTMed

Microvast Reports Third Quarter 2026 Financial Results

Microvast Holdings, Inc. (MVST) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Microvast Reports Third Quarter 2026 Financial Results Houston, Texas, USA — Microvast Holdings, Inc. (NASDAQ:MVST) (“Microvast” or the “Company”), today announced its unaudited consolidated financial results for the quarter ended September 30, 2026 (“Q3 2026”). “The

$MVSTMed

Microvast Reports Second Quarter 2026 Financial Results

Microvast Holdings, Inc. (MVST) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Microvast Reports Second Quarter 2026 Financial Results Houston, Texas, USA — Microvast Holdings, Inc. (NASDAQ:MVST) (“Microvast” or the “Company”), a global leader in advanced battery technologies, announced today its unaudited consolidated financial results for the

$DDOGHighAI 9/10

“Missing Forest-for-the-Trees”: Datadog Sinks 17% in a Week as Its Biggest AI Customer Cuts Back

Datadog (DDOG) stock fell 17% in a week after reporting 35% Q3 revenue growth to $1.2B but guiding Q4 revenue to $1.19-1.2B, roughly flat. The decline was driven by its largest AI customer reducing usage, though growth outside this customer is accelerating. Cloudflare (NET) reported strong Q3 results and a rising Q4 outlook, suggesting the slowdown may be isolated. Datadog trades at 60x forward earnings, below its usual multiple.

$NOVTHighAI 8/10

Novanta (NOVT) Q3 2026 Earnings Call Transcript

Novanta (NOVT) reported Q3 2026 revenue of $305M, up 23%, with organic growth of 10%. Adjusted EBITDA rose 38% to $80M, and adjusted EPS increased 21% to $1.05. The company acquired Riverpoint Medical, expanding its medical end markets to 53% of revenue. Customer bookings grew 29%, and backlog reached $543M. Operating cash flow tripled year-over-year to $156M. Novanta expects full-year 2027 gross margin expansion and strong earnings growth, driven by new products and acquisitions.